Current status and perspectives on the development of therapeutic agents for Alzheimer's disease

Folia Pharmacologica Japonica

Volumn 123, Issue 6, 2004, Pages 421-427

  Hirouchi, Masaaki ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Amyloid peptide; Nonsteroidal anti inflammatory drug; Secretase

Indexed keywords

1 (BENZO[B]THIEN 5 YL) 2 (2 DIETHYLAMINOETHOXY)ETHANOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN VACCINE; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; GP 37267; IBUPROFEN; ICOSAPENTAENOIC ACID ETHYL ESTER; MEMANTINE; METAL CHELATE; MONOAMINE REUPTAKE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; NS 2330; ONO 2506PO; RIVASTIGMINE; SULINDAC; SUN Y7017; TACRINE; UNCLASSIFIED DRUG; VACCINE;

ALZHEIMER DISEASE; ANALGESIA; BETA SHEET; CLINICAL TRIAL; COGNITIVE DEFECT; COMPETITIVE INHIBITION; DISEASE SEVERITY; DRUG MARKETING; DRUG MECHANISM; ENZYME INHIBITION; EUROPE; HUMAN; INHIBITION KINETICS; JAPAN; PATHOLOGICAL ANATOMY; PROTEIN EXPRESSION; PROTEIN PROCESSING; RECEPTOR BLOCKING; REVIEW; SENILE PLAQUE; UNITED STATES;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CHOLINESTERASE INHIBITORS; DIETHYLAMINES; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION; THIOPHENES;

EID: 3042788761     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.123.421     Document Type: Review

References (26)

1. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003;2:539-547.
2. Suh Y-H, Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev. 2002;54:469-525.
3. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003; 169:557-564.
4. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003; 9:275-308.
5. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
6. Ono S, Yamafuji T, Chaki H, et al. A new cognition-enhancing agent, (R)-(-)-1-(benzo [b] thiophen-5-yl)-2-[2-(N, N-diethylamino) ethoxy] ethanol hydrochloride.: effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions. Biol Pharm Bull. 1995; 18:1779-1783.
7. Yamamuro A, Ago Y, Maeda S, et al. Protective effect of T-588 on toxic damage by serum deprivation and amyloid-β protein in cultured neurons. J Pharmacol Sci. 2003;92:153-156.
8. Tateishi N, Mori T, Kagamiishi Y, et al. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab. 2002;22:723-734.
9. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741-766.
10. Citron M. β-Secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res. 2002; 70:373-379.
11. Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the γ-secretase complex. Nature. 2003;422:438-441.
12. Allinson TMJ, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein α-secretases. J Neurosci Res. 2003;74:342-352.
13. Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol. 2004;486:9-17.
14. Akaike A, Maeda T, Kaneko S, Tamura Y. Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons. Jpn J Pharmacol. 1998;76:219-222.
15. John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL. Human β-secretase (BACE) and BACE inhibitors. J Med Chem. 2003;46:4625-4630.
16. Lanz TA, Himes CS, Pallante G, et al. The γ-secretase inhibitor N-EN-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther. 2003;305:864-871.
17. Petit A, Pasini A, Costa CA, et al. JLK isocoumarin inhibitors: selective γ-secretase inhibitors that do not interfere with Notch pathway in vitro or in vivo. J Neurosci Res. 2003;74:370-377.
18. Tian G, Ghanekar SV, Aharony D, et al. The mechanism of γ-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. J Biol Chem. 2003;278:28968-28975.
19. Nakagami Y, Nishimura S, Murasugi T, et al. A novel β-sheet breaker, RS-0406, reverses amyloid β-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol. 2002; 137:676-682.
20. Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Science. 2003;302:834-838.
21. 42 generation. J Biol Chem. 2003;278:18664-18670.
22. Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J Neurosci. 2003;23:9796-9804.
23. Qin W, Ho L, Pompl PN, et al. Cyclooxygenase (COX)-2 and COX-1 potentiate β-amyloid peptide generation through mechanisms that involve γ-secretase activity. J Biol Chem. 2003;278:50970-50977.
24. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogensis and treatment of Alzheimer's disease. Trends Mol Med. 2003;94-101.
25. Rivas-Vazquez RA, Mendez C, Rey GJ, et al. Mild cognitive impairment: new neuropsychological and pharmacological target. Arch Clin Neuropsychol. 2004;19:11-27.